← Eichor
Study identifier: NCT07693075 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Efficacy and Safety of Simultaneous Integrated Boost Radiotherapy in HR/VHR Prostate Cancer With EPLNI

Condition: Prostate Cancer Patients Treated by Radiotherapy  ·  Sponsor: Ain Shams University

PhasePhase 2
Planned participants30
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The aim of this study is to evaluate the efficacy and safety of hypofractionated simultaneous integrated boost volumetric arc radiation therapy (SIB - VMAT) for high-risk and very high-risk localized prostate cancer in terms of: 1. Acute and late gastrointestinal and genitourinary toxicities. 2. Evaluate the efficacy in terms of early bPFS. 3. Dosimetric evaluation in terms of target coverage and organs at risk sparing

This description comes directly from the study's public registry record.

Talk to the study team

Mohamed Alhefny, MD  ·  +201228169673  ·  Alhefny@med.asu.edu.eg

Ahmed Sohaib, MD  ·  +201060406063  ·  dr.ahmed.sohaib@gmail.com

Always discuss trial participation with your own doctor first.

Locations (3)

Faculty of Medicine, Ain Shams UniversityCairo, EgyptRecruiting
Faculty of Medicine - Menoufia UniversityShibīn al Kawm, EgyptRecruiting
Faculty of Medicine - Sohag UniversitySohag, EgyptRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07693075